In pulmonary hypertension (PH), defective plasma von Willebrand factor (vWF) lacking the larger multimers with increased concentration of low-molecular-weight fractions (LMW) has been reported, although the mechanisms involved are not completely known. Altered platelet behavior may be involved in this alteration; this hypothesis was investigated in 10 patients with PH associated with chronic hypoxemia and erythrocytosis (age 13 to 51 years, mean pulmonary artery pressure 38 to 98 mmHg). The possible influence of the hematocrit (Hct) and decreased oxygen saturation (SpO2) on vWF abnormalities was examined. Patients were evaluated before and after therapeutic hemodilution. vWF alterations were quantified using the ratio of LMW/total multimers (densitometric analysis of luminographs after Western blotting). Platelet count and activation state (plasma levels of f-thromboglobulin, enzyme-linked immunosorbent assay), the Hct and SpO2 were also assessed before and after hemodilution. Platelet activation and consumption were sug-
crease of high molecular weight fractions, with appearance of unusually large multimers (4, 5) . In contrast, the larger multimers, which are the most active ones from the biologic point of view may be lacking in inherited and acquired disorders, with impairment of hemostasis (6, 7) .
In patients with pulmonary hypertension, disappearance of high-molecular-weight vWF multimers from plasma has been reported by several authors, including ourselves (8) (9) (10) . Although the mechanisms of altered vWF structure in this disorder have not been completely clarified, improvement has been observed following continuous prostacyclin infusion (10) . In secondary pulmonary hypertension associated with hypoxemia, variables with known impact on endothelial and platelet physiology such as hypoxia itself and altered blood viscosity (erythrocytosis) could potentially impact on the structure of circulating vWF. Previously, we demonstrated decreased platelet count and survival in these patients, with improvement following therapeutical hemodilution (11) . It is not known whether platelet and vWF abnormalities observed in these patients are related phenomena. Knowledge of whether or not oxygen desaturation, erythrocytosis, and altered platelet turnover influence vWF multimeric composition in vivo could provide insights on the mechanisms underlying vWF abnormalities in these patients. Such correlations have not been investigated, however. In the present study, we looked for possible associations of plasma vWF multimeric abnormalities with the magnitude of oxygen desaturation, erythrocytosis, decreased platelet count, and platelet activation in chronically oxygen-desaturated pulmonary hypertensive subjects and examined the effects of therapeutic hemodilution on all variables under investigation.
METHODS

Study Population
Ten patients with pulmonary hypertension associated with congenital heart disease (right-toleft shunt), chronic hypoxemia and erythrocytosis (so-called Eisenmenger's syndrome) entered the study consecutively. Patients were under ambulatory care at the Heart Institute, Sao Paulo, Brazil. Pediatric and adult patients were enrolled if the mean pulmonary arterial pressure was above 30 mmHg at rest, during cardiac catheterization. Only patients with high hematocrit levels requiring hemodilutional procedures for relief of hyperviscosity-related symptoms were included. For biochemical determinations, blood collection was carried out on an outpatient basis. No patients were under hospital or emergency care nor were they receiving anticoagulants or prostacyclin by the time of blood sampling. Twenty healthy controls matched for age were also enrolled. All subjects were informed about the research purpose of blood collection and gave their consent. The study protocol was approved by the Scientific Committee of the Heart Institute.
Study Protocol and Hemodilution Procedure
Patients were evaluated in steady conditions before and 4 days after hemodilution to avoid any influence of the replacement solution on the biochemical determinations. Hemodilution was performed only for relief of hyperviscosity-related symptoms, not for research purposes. The pro-cedure was planned to exchange 10% of patient's total blood volume (previous radioisotopic measurement) using an equal volume of dextran 40,000 M.W. Withdrawal and replacement were performed simultaneously. The total time of hemodilution was 1 hour on average and heart rate, blood pressure, and peripheral oxygen saturation (SpO2, pulse oximetry) were monitored. Blood samples for hematocrit determination, platelet count, and biochemical analyses were collected before and 4 days after hemodilution. SPO2 was measured in both conditions, at the same time of blood sampling.
Plasma Obtainment
Blood samples were collected without tourniquet in 1:10 volume 3.8% sodium citrate, in the presence of protease inhibitors: 5 mM edetic acid, 6 mM N-ethylmaleimide, 1 mM phenylmethylsulphonyl fluoride, 20 U/mL aprotinin, and 0.25 mM leupeptin. Plasma was immediately separated by centrifugation at 3,000 g for 20 minutes and stored at -80°C until use.
Biochemical Analyses
Plasma von Willebrand factor antigen (vWF:Ag) and P-thromboglobulin, a marker of platelet release reaction were measured by enzyme-linked immunosorbent assay (Diagnostica Stago, Asnieres, France). Results were expressed as U/dL and U/mL respectively. The multimeric composition of plasma vWF was analyzed by Western immunoblotting with few modifications of previously described protocol (9) . After electrophoresis in SDS 1% agarose gels, proteins were transferred to nitrocellulose membranes at a constant current of 200 mA for 14 hours, using a mini-electrotransfer unit (Hoefer TE22 transphor unit, Amersham Biosciences, Buckinghamshire, UK) to keep a constant temperature of 15°C. After blocking the membranes, vWF protein (non reduced) was probed with 1:300 dilution of rabbit anti-human vWF polyclonal antibody (Dako Corporation, Carpinteria, CA, USA). All steps for protein visualization followed the instructions of the chemiluminescence kit manufacturer (ECL Western blot detection kit, Amersham Biosciences). Peroxidase-conjugated secondary antibody was used at 1:2,000 dilution. Membranes were reacted with a high sensitivity (luminol) detection system and exposed to x-ray films for 10 seconds. Luminographs were then subjected to densitometric analysis in a laser densitometer (Ultroscan XL, Bromma, Sweden) and quantitative analysis of vWF multimers was carried out by calculating the density of low molecular weight fractions (five bands migrating above IgM, 950 kDa) relative to total multimer density (LMW/Total). All experiments were performed in duplicate or triplicate and final results expressed as the mean value. Saturation of the luminographs was prevented by limiting the exposure time. High-density luminographs used to prepare the illustration were not used for densitometric analysis.
Statistical Analysis
Results are presented as mean + SD. To decide about use of parametric or nonparametric statistics, all variables were tested for closeness to the normal distribution. Comparisons between patients and controls were performed using the Student's t-test or the Mann-Whitney test. Pairwise comparisons of data before and after hemodilution were performed using the t-test or the Wilcoxon signed rank test. The variable [vWF LMW/Total] was confirmed as having a normal distribution. Factors possibly influencing this variable were first tested by simple linear regression with calculation of the coefficient of determination, [r2]. Then, a multiple linear regression model was adjusted using a stepwise procedure for independent variable inclusion. The goodness of fit was tested by ANOVA and calculation of [r2]. All tests were two-sided and a significance level of 0.05 was assumed.
RESULTS
General diagnostic data of ten patients who were enrolled in the study are depicted in Table  1 . Laboratory data are shown in baseline condition, decreased SpO2 in patients was associated with high hematocrit levels and low platelet count. A state of chronic platelet activation was suggested by increased plasma levels of ,B-thromboglobulin. Plasma vWF:Ag was increased although its multimeric compositions was defective, with loss of high molecular weight multimers and increased concentration of low-molecular-weight fractions (LMW/Total, Table 2 ). Attempts were made to identify variables with possible impact on vWF multimeric composition, firstly using univariate analysis. Platelet count and SpO2 correlated negatively with the magnitude of vWF multimeric abnormalities (p<0.01, Fig. 1 ). The hematocrit and plasma f3-thromboglobulin did not correlate significantly with vWF LMW/Total multimer ratio (r2=0.31, p=0.0897, and r2=0.28, p=0.1469, respectively). Stepwise multiple regression analysis showed that both platelet count and SpO2 were independently related to vWF multimeric abnormalities. The inclusion of SpO2 in the single variable model (platelet count, r2=0.62, p=0.0066) resulted in a significant improvement of fit (r2=0.81, p=0.0031 for the two-variable model). Hemodilution was performed in all patients of the study and resulted in a significant improvement of symptoms; in particular, headache, arthralgia, fatigue and a sensation of congestion in the upper region of the chest and neck. The procedure was followed by a significant decrease in the hematocrit associated with an increase in platelet count, in the absence of any significant changes in SpO2 or plasma f-thromboglobulin (Table 2) . Although plasma vWF:Ag did not change, a slight but significant improvement was observed in the multimeric pattern, with increased density of the intermediate and high molecular weight fractions ( Fig. 2) and decreased relative proportion of the low molecular weight forms ( Table 2 ). It is noticeable that in spite of the significant improvement of vWF LMW/Total multimer ratio and platelet count, both variables still remained considerably altered in comparison with control values as shown in Table 2 and illustrated in Fig. 2 .
DISCUSSION
In our patients, a state of endothelial activation/perturbation was suggested by increased circulating levels of vWF:Ag, a marker of endothelial dysfunction. Also, a state of chronic platelet activation and consumption was suggested by increased plasma levels of ,-thromboglobulin and decreased platelet count comy = -0.0071x + 1.1051 r2= 0.5981 p = 0.0085 pared with controls. Chronic platelet consumption was proposed in a previous study of ours as a possible explanation for decreased platelet count based on the observation of increased platelet turnover in similar patients (11) . On the other hand, hypoxia itself did not seem to account for platelet abnormalities in the present study, because neither 3-thromboglobulin nor platelet count correlated significantly with SpO2 (not shown). It could be speculated that platelet activation occurs throughout the narrowed pulmonary microvessels under adverse hemorheological conditions in the presence of heightened hematocrit. An increase in platelet count was in fact observed following hemodilution, in the absence of any significant change in SpO2. Improvement of platelet survival has been demonstrated after hemodilution in patients with the same disorder (11) .
The present study brings up possibilities regarding the mechanisms of vWF multimeric abnormalities in pulmonary hypertension associated with hypoxia, erythrocytosis and decreased platelet count. Evidence was provided that to some extent, vWF structural abnormalities were related to hypoxia and altered platelet behavior in the patient group we analyzed. First, vWF multimeric abnormalities correlated significantly with oxygen desaturation and decreased platelet count in both univariate and multivariate analyses. Second, the significant rise in platelet count following hemodilution was associated with improvement of the multimeric abnormalities in group analysis and individual cases as illustrated in Fig. 2 . Since hemodilution did not result in any significant change in SpO2, the association between platelet and vWF abnormalities became more evident. On the other hand, persistent hy-poxia after hemodilution might have accounted in part for the residual abnormalities of vWF multimers.
Several mechanisms have been proposed to explain the disappearance of larger vWF multimers from plasma in patients with pulmonary hypertension. Previous observations of ours suggest that in pulmonary hypertensive subjects, vWF multimers undergo abnormal proteolytic cleavage (12) . In a recent study involving patients who were not supposed to have hypoxemia or erythrocytosis, the authors failed to demonstrate an increase in the activity of vWF-cleaving protease. Based on this, they proposed that local increase in shear rates related to pulmonary microvascular damage could induce an unfolding of vWF molecule, making cleavage sites more accessible to the action of proteases (10) . In that study however, no information was provided regarding the state of platelet activation. In this way, the demonstrated improvement of vWF abnormalities following prostacyclin administration could be explained by normalization of platelet function, an expected effect of prostacyclin treatment (13) .
Very similar alterations of platelet function and vWF multimers have been observed under increased shear stress conditions in patients with aortic valve stenosis, with improvement after surgical correction (14) . In fact, shear forces may directly affect the molecular conformation of large vWF multimers (15, 16) with exposure of the proteolytically sensitive bond between Tyr 842 and Met 843 (17) . An alternative or more likely additive explanation is that vWF Al-domain may interact with platelet glycoprotein Ibox under flow conditions with high shear rate (18) . Upon platelet activation, immobilized vWF multimers may contribute to the formation of microaggregates that are removed from the circulation. Such mechanism may favor vWF degradation by the action of natural vWF-cleaving protease. Of notice, in type 2B von Willebrand's disease, large vWF multimers disappear from plasma as a result of single point mutations that favor the interaction between Al-domain and GPIbcx even in the absence of increased shear rates. The final result involves transient platelet sequestration and vWF multimer degradation (19) (20) (21) (22) . We speculate that in our patients and possibly some of those reported by Veyradier and colleagues (10) , short-lived interactions of vWF multimers with platelet membrane might have occurred with partial reversion by hemodilution or prostacyclin, thus explaining the improvement of multimeric composition following treatment. In contrast, activation-dependent and therefore more stable interactions of multimers with platelet membrane glycoproteins might explain the residual abnormalities observed in our patients after treatment, taking into account that an activated state of platelets was still present.
The association between decreased oxygen tension and vWF abnormalities observed in our patients may reflect the impact of hypoxia on endothelial cell biologic behavior. Hypoxia has been shown to promote a cascade of biologic events that results in enhanced ability of the endothelium to recruit circulating elements, mainly neutrophils (23) . Local release of neutrophilderived proteases could result in abnormal proteolysis of vWF, thereby explaining the loss of larger multimers (24, 25) . An alternative explanation is the release of unprocessed vWF multimers lacking the high molecular weight forms. In this way, hypoxia has been shown to induce exocytosis of endothelial Weibel-Palade bodies with release of vWF and P-selectin (26) . Interestingly in addition, hypoxia seems to promote the assembly of secretion pores that represent connections of the Weibel-Palade bodies with the extracellular milieu (27) . Whatever mechanisms operate in vivo in these patients, residual vWF abnormalities following hemodilution might be partly explained by persistence of hypoxic conditions. Some clinical points could be raised of what these laboratory findings and recovery of an abnormal pattern actually mean for the patients. Furthermore, because the observed abnormalities persisted to some extent after hemodilution a question could be raised about the real benefits of the procedure in these patients with pulmonary hypertension-associated erythrocytosis. The use of repeated phlebotomies in patients with Eisenmenger's syndrome has been strongly discouraged since iron depletion-associated microcytosis may result in a significant increase in blood viscosity and worsening of hyperviscosityrelated symptoms (28) . Therefore, there is a general agreement that hemodilution should be performed only in symptomatic patients, not to achieve a given hematocrit level or correct specific laboratory abnormalities. Following this consensus in the present study, it was interesting to observe and possibly relevant from the pathophysiologic point of view that platelet and vWF abnormalities improved as an additional effect of treatment. Although our data do not provide information of how long the effects of he-modilution on the variables under investigation lasted, we observed that the hematocrit returned to pre-hemodilution levels after 2 to 3 months on average.
If the platelet-vWF interaction hypothesis holds, we believe that recovery of an abnormal pattern may have pathophysiological and therapeutic implications. From the pathophysiologic point of view, several authors have emphasized the role of thrombosis in the development and progression of pulmonary arteriopathy (29) (30) (31) (32) . In this way, improvement of mechanisms that are part of the prothrombotic scenario may theoretically result in long-term benefits. From the therapeutic side, analysis of the present results and previously reported data suggesting platelet participation in the pathophysiology of pulmonary vascular disease (33) (34) (35) could bring up a discussion about the use of antiplatelet drugs in this disorder, in view of the fact that some of these patients have an increased bleeding tendency (28) . Still in the therapeutic field, based on our observation of the influence of SpO2 on the multimeric composition of vWF, we speculate about the possible benefits of chronic oxygen administration in this context. We are currently investigating this.
In conclusion, data of the present study suggest a relationship between vWF multimeric abnormalities and altered platelet behavior in chronically hypoxic pulmonary hypertensive patients. Hypoxia itself seems to influence plasma vWF composition as well. Further studies are necessary for a better understanding of these relationships at the cellular and molecular levels.
